Hofseth Biocare Valuation
| HBC Stock | NOK 2.30 0.04 1.71% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Hofseth Biocare ASA retains a regular Real Value of 2.34 per share. The prevalent price of the firm is 2.3. Our model calculates the value of Hofseth Biocare ASA from evaluating the firm fundamentals such as Return On Equity of -0.95, current valuation of 1.03 B, and Return On Asset of -0.19 as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Hofseth Biocare's price fluctuation is dangerous at this time. Calculation of the real value of Hofseth Biocare ASA is based on 3 months time horizon. Increasing Hofseth Biocare's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Hofseth stock is determined by what a typical buyer is willing to pay for full or partial control of Hofseth Biocare ASA. Since Hofseth Biocare is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hofseth Stock. However, Hofseth Biocare's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.3 | Real 2.34 | Hype 2.3 | Naive 2.26 |
The intrinsic value of Hofseth Biocare's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Hofseth Biocare's stock price.
Estimating the potential upside or downside of Hofseth Biocare ASA helps investors to forecast how Hofseth stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hofseth Biocare more accurately as focusing exclusively on Hofseth Biocare's fundamentals will not take into account other important factors: Hofseth Biocare Total Value Analysis
Hofseth Biocare ASA is currently forecasted to have takeover price of 1.03 B with market capitalization of 1.1 B, debt of 123.31 M, and cash on hands of 36.52 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Hofseth Biocare fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.03 B | 1.1 B | 123.31 M | 36.52 M |
Hofseth Biocare Investor Information
About 53.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.38. Hofseth Biocare ASA had not issued any dividends in recent years. The entity had 866:863 split on the 16th of October 2020. Based on the measurements of operating efficiency obtained from Hofseth Biocare's historical financial statements, Hofseth Biocare ASA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Hofseth Biocare Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Hofseth Biocare has an asset utilization ratio of 21.06 percent. This suggests that the Company is making 0.21 for each dollar of assets. An increasing asset utilization means that Hofseth Biocare ASA is more efficient with each dollar of assets it utilizes for everyday operations.Hofseth Biocare Ownership Allocation
Hofseth Biocare ASA has a total of 395.08 Million outstanding shares. Hofseth Biocare secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Hofseth Biocare Profitability Analysis
The company reported the revenue of 87.62 M. Net Loss for the year was (126.46 M) with profit before overhead, payroll, taxes, and interest of 28.51 M.About Hofseth Biocare Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Hofseth Biocare ASA. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Hofseth Biocare ASA based exclusively on its fundamental and basic technical indicators. By analyzing Hofseth Biocare's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Hofseth Biocare's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Hofseth Biocare. We calculate exposure to Hofseth Biocare's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Hofseth Biocare's related companies.Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. The company was founded in 2000 and is headquartered in lesund, Norway. HOFSETH BIOCARE operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 44 people.
8 Steps to conduct Hofseth Biocare's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Hofseth Biocare's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Hofseth Biocare's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Hofseth Biocare's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Hofseth Biocare's revenue streams: Identify Hofseth Biocare's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Hofseth Biocare's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Hofseth Biocare's growth potential: Evaluate Hofseth Biocare's management, business model, and growth potential.
- Determine Hofseth Biocare's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Hofseth Biocare's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Hofseth Stock
Hofseth Biocare financial ratios help investors to determine whether Hofseth Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hofseth with respect to the benefits of owning Hofseth Biocare security.